Tricida Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Tricida stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCDA, but not buy additional shares or sell existing shares.
View analyst ratings for Tricida or view top-rated stocks.

Wall Street analysts have given Tricida a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tricida wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Tricida saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 3,280,000 shares, a decline of 21.5% from the June 15th total of 4,180,000 shares. Based on an average daily volume of 363,300 shares, the short-interest ratio is presently 9.0 days. Currently, 8.3% of the company's stock are sold short.
View Tricida's Short Interest.

Tricida is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Tricida.

Tricida, Inc. (NASDAQ:TCDA) posted its quarterly earnings data on Thursday, May, 6th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.17.
View Tricida's earnings history.

Tricida's stock was trading at $28.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TCDA shares have decreased by 85.0% and is now trading at $4.21.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 1 year price targets for Tricida's shares. Their forecasts range from $8.00 to $40.00. On average, they expect Tricida's stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 363.2% from the stock's current price.
View analysts' price targets for Tricida or view top-rated stocks among Wall Street analysts.

2 employees have rated Tricida CEO Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among Tricida's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Tricida include Prometheus Biosciences (RXDX), ADVANZ PHARMA (CXRXF), Mersana Therapeutics (MRSN), Avidity Biosciences (RNA), Annovis Bio (ANVS), Arcturus Therapeutics (ARCT), Aclaris Therapeutics (ACRS), IVERIC bio (ISEE), RAPT Therapeutics (RAPT), Annexon (ANNX), Gracell Biotechnologies (GRCL), Travere Therapeutics (TVTX), Akero Therapeutics (AKRO), Summit Therapeutics (SMMT) and Radius Health (RDUS).
View all of TCDA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

(TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TCDA stock can currently be purchased for approximately $4.21.

Tricida has a market capitalization of $211.64 million. The company earns $-264,790,000.00 in net income (profit) each year or ($5.29) on an earnings per share basis.

Tricida employs 64 workers across the globe.

The official website for Tricida is www.tricida.com.

Tricida is headquartered at 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]